West Nile Virus Retains Position as Primary Mosquito-Borne Threat in U.S., CDC Data Shows

Key facts

Reporting by Infectious Disease Special Edition highlights that West Nile virus has sustained its standing as the top arboviral pathogen in the United States. In reviewing current guidance from the Centers for Disease Control and Prevention (CDC), the report emphasizes that severe clinical manifestations are strongly correlated with individual patient risk profiles rather than uniform population-wide susceptibility.

According to reporting by Infectious Disease Special Edition, health authorities specifically noted that "some people are at higher risk due to factors like age, underlying medical conditions, and level of immunosuppression." This risk stratification remains central to public health messaging as federal and state agencies work to reduce hospitalizations associated with neuroinvasive arboviral infections.

To mitigate transmission, public health officials outlined targeted preventive actions for both individuals and communities. The CDC strategy focuses on minimizing mosquito exposure through behavioral interventions and environmental controls. Recommended measures include applying Environmental Protection Agency (EPA)-registered insect repellents containing active ingredients such as DEET, picaridin, or oil of lemon eucalyptus; wearing long-sleeved shirts and loose-fitting trousers during peak mosquito activity hours; and eliminating stagnant water containers around residential properties where mosquitoes lay eggs.

Furthermore, healthcare providers are urged to maintain a high index of clinical suspicion for West Nile virus when evaluating patients presenting with unexplained fever, acute neurological symptoms, or meningitis-like illness during late summer and autumn months, when vector populations are most active.

Why it matters

The sustained status of West Nile virus as the leading domestic arbovirus underlines persistent challenges in public health vector control, municipal infrastructure, and clinical risk management. Unlike exotic arboviruses such as dengue, chikungunya, or Zika, which are predominantly imported by international travelers, West Nile virus is fully endemic within the contiguous United States, maintaining permanent environmental reservoirs in native wild bird populations and local mosquito vectors.

From a clinical and economic perspective, West Nile virus exerts a disproportionate toll on adult intensive care units and long-term rehabilitation facilities. While the majority of cases are subclinical or present as self-limiting febrile illness, neuroinvasive infections—comprising encephalitis, meningitis, and acute flaccid paralysis—frequently result in prolonged hospitalization, permanent neurological deficits, or death. Advanced age remains the most severe independent risk factor for neuroinvasive disease, with mortality rates among hospitalized elderly patients reaching significant levels. For immunocompromised individuals, such as solid organ transplant recipients or patients undergoing chemotherapy, the risk of unmitigated viral replication in the central nervous system presents severe management challenges.

For local municipalities, maintaining active vector control programs requires consistent public funding and staffing. Mosquito control districts must balance adulticide spraying and larvicide applications with environmental regulations and community communication. Additionally, the persistence of West Nile virus complicates blood supply safety, requiring blood donation centers across the country to perform universal nucleic acid testing during active transmission seasons to prevent transfusion-transmitted infections.

West Nile virus is a single-stranded RNA virus belonging to the genus Flavivirus and the family Flaviviridae, placing it in the same viral family as yellow fever, dengue, and Saint Louis encephalitis viruses. First isolated in 1937 in the West Nile district of Uganda, the virus was historically restricted to parts of Africa, the Middle East, Southern Europe, and Western Asia.

The virus made its initial appearance in the Western Hemisphere in late summer 1999, when an outbreak of unexplained encephalitis was detected in New York City. Over the subsequent five years, the pathogen spread rapidly across the North American continent, establishing endemic transmission cycles across all 48 contiguous states, as well as parts of Canada, Mexico, and the Caribbean.

The biological transmission cycle of West Nile virus primarily involves Culex species mosquitoes—most notably Culex pipiens in the northern United States, Culex quinquefasciatus in the south, and Culex tarsalis in western agricultural regions—and wild birds, particularly corvids such as crows, jays, and magpies. Birds serve as amplifying hosts, developing high-level viremia capable of infecting feeding mosquitoes. Humans, horses, and other mammals are considered dead-end hosts because they do not produce sufficient viral loads in their bloodstream to re-infect mosquitoes, meaning human-to-human transmission does not occur through casual contact.

To monitor arboviral activity nationwide, the CDC operates ArboNET, a cooperative national surveillance system launched in 2000. ArboNET collects data from state and local health departments regarding human cases, veterinary infections, dead bird sightings, mosquito pool testing, and sentinel chicken flock seroconversion. Over the past quarter-century, ArboNET has recorded tens of thousands of neuroinvasive West Nile virus cases and thousands of deaths, establishing West Nile as the primary driver of domestic arboviral morbidity in the United States, far surpassing native competitors such as Eastern equine encephalitis, La Crosse virus, and Saint Louis encephalitis.

Treatment for West Nile virus remains strictly supportive, as no specific antiviral therapies or human vaccines have received approval from the U.S. Food and Drug Administration. Standard clinical management focuses on symptom relief, intravenous fluids, antipyretics, and, for severe neuroinvasive illness, intensive respiratory support and management of intracranial pressure.

Reaction

Public health agencies and medical associations consistently reiterate the necessity of preventive vigilance as vector activity extends through late September and early October. State departments of health across high-incidence corridors frequently issue localized advisory notices urging residents to take precaution during evening and early morning hours when Culex mosquitoes are most active.

In response to ongoing CDC assessments, vector control agencies emphasize community involvement in source reduction—the systematic removal of standing water from artificial containers, discarded tires, clogged gutters, and bird baths. Local mosquito abatement districts point out that public participation in eliminating breeding sites is essential to complementing municipal chemical treatment efforts.

Clinical groups, including infectious disease specialists and geriatric healthcare providers, advocate for heightened diagnostic testing among vulnerable populations. Because symptoms of West Nile fever can mimic influenza, COVID-19, or other seasonal viral illnesses, medical authorities stress the importance of ordering specific IgM antibody testing on serum and cerebrospinal fluid when evaluating high-risk patients who present with acute neurological deficits or unexplained febrile illnesses during vector season.

What we don't know yet

Despite decades of research and continuous surveillance, several key operational and scientific uncertainties surround West Nile virus management:

What to watch

In the coming months, public health analysts, healthcare providers, and policy makers will monitor several critical milestones:

This report is based on reporting published by Infectious Disease Special Edition (idse.net).